Eyes and ears
82 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 0.25% RCI001 Ophthalmic Solution for dry eye syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1.5 x 10^6 UC-MSC + CM for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 4D-110 for choroideremia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 5 x 10^6 UC-MSC + CM for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV-mediated REP1 gene replacement for choroideremia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV2-hRPE65v2,voretigene neparvovec-rzyl for leber congenital amaurosis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ACDN-01 for cone-rod dystrophies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ACDN-01 for stargardt disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aceclidine for myopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Aceclidine for presbyopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Aceclidine+Brimonidine combination ophthalmic solution for myopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Aceclidine+Brimonidine combination ophthalmic solution for presbyopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| ADVM-022 for choroidal neovascularization | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ADVM-022 for wet macular degeneration | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atropine sulfate for myopia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous iPSC-derived RPE for macular degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB112 for choroideremia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bimatoprost ophthalmic solution 0.01% YSBP for glaucoma, open-angle | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal neovascularization | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for corneal opacity | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft + CALEC Transplant + Cultivation of Limbal epithelial cells into a graft for limbal stem cell deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BRIMOCHOL PF eye drops; CARBACHOL PF eye drops; Brimonidine eye drops; Placebo for presbyopia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brimonidine for myopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brimonidine for presbyopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brinretigene Vesgedparvovec for eye abnormalities | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brinretigene Vesgedparvovec for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brinretigene Vesgedparvovec for retinal degeneration | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BS01 for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Citicoline eye drops 2% for glaucoma, open-angle | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Clemastine for eye pain | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CTO0308 for myopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cultured limbal stem cells Transplantation for limbal stem cell deficiency | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DT-168 for fuchs' endothelial dystrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ER-100 epigenetic therapy for glaucoma, open-angle | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ER-100 epigenetic therapy for retinal diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eyecyte-RPE™ for geographic atrophy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FEMJA transplatation for limbal stem cell deficiency | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Intensified medical follow-up and glucose-lowering drugs for retinal diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Kinezodianone R hydrochloride for glaucoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Licaminlimab for dry eye syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LinkCor Bioengineered Corneal Implant for keratoconus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LNZ101 (Aceclidine /Brimonidine) ophthalmic solution for presbyopia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide riboside for glaucoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NT-101 ophthalmic solution for macular degeneration | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose + OCU400 Med Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Low Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Low Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Med Dose for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Med Dose for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Second Eye Dosing for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU400 Second Eye Dosing for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OCU410 for geographic atrophy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OLN324 for macular degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OpRegen for geographic atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OpRegen for macular degeneration | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prima for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PRIMA Bionic Vision System for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PRIMA Products for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PRIMA Products for stargardt disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PST-611 for geographic atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Puliretgene Parvec for retinitis pigmentosa | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rAAV2.REP1 for choroideremia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rAAV2.REP1 for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| rAAV2.REP1 vector for choroideremia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RTx-015 for retinitis pigmentosa | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SB-007 for stargardt disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SHJ002 for myopia, degenerative | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sirolimus for corneal dystrophies, hereditary | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Subconjuntival injection of expanded allogenic adult adipose tissue-derived mesenchymal stem cells (ASC for dry eye syndromes | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Taurine for cataract | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| The new type of filtering glasses can efficiently filter out the high-energy blue and green light within a narrow wavelength band. for asthenopia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Timrepigene emparvovec for choroideremia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Vehicle for myopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Vehicle for presbyopia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Vehicle proprietary ophthalmic solution for myopia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Vehicle proprietary ophthalmic solution for presbyopia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| voretigene neparvovec-rzyl for leber congenital amaurosis | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |